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Laminin (LM)-332 is an extracellular matrix protein that plays a structural role in normal tissues and is also important in
facilitating recovery of epithelia from injury. We have shown that expression of LM-332 is up-regulated during renal epithelial
regeneration after ischemic injury, but the molecular signals that control expression are unknown. Here, we demonstrate that
in Madin-Darby canine kidney (MDCK) epithelial cells LM-332 expression occurs only in subconﬂuent cultures and is
turned-off after a polarized epithelium has formed. Addition of active transforming growth factor (TGF)-1 to conﬂuent
MDCK monolayers is sufﬁcient to induce transcription of the LM 3 gene and LM-332 protein expression via the TGF- type
I receptor (TR-I) and the Smad2–Smad4 complex. Signiﬁcantly, we show that expression of LM-332 in MDCK cells is an
autocrine response to endogenous TGF-1 secretion and activation mediated by integrin V3 because neutralizing antibodies
block LM-332 production in subconﬂuent cells. In conﬂuent cells, latent TGF-1 is secreted apically, whereas TR-I and integrin
V3 are localized basolaterally. Disruption of the epithelial barrier by mechanical injury activates TGF-1, leading to LM-332
expression. Together, our data suggest a novel mechanism for triggering the production of LM-332 after epithelial injury.
INTRODUCTION
Epithelial cells form selective barriers between the environ-
ment and the internal milieu of organs, including kidney,
breast, skin, and intestine (Schock and Perrimon, 2002; Bry-
ant and Mostov, 2008). The most important differentiated
characteristic of epithelial cells is their apical–basal polarity.
Within an epithelium, each cell is organized along an axis
orthogonal to the surface of the epithelium such that the
protein and lipid compositions of the apical, lateral, and
basal plasma membrane domains are unique and organelles
are distributed asymmetrically throughout the cytoplasm.
Polarization is driven by the intrinsic activity of three polariza-
tion complexes as well as extrinsic spatial cues provided by
adhesive interactions between adjacent cells and the underly-
ing extracellular matrix (Jamora and Fuchs, 2002; Nelson, 2003,
2009). In normal epithelia, the matrix underlying the epithe-
lium is organized into a basal lamina composed of interlocking
networks of laminins and collagen type IV, along with contri-
butions from proteoglycans such as perlecan and other mole-
cules (Yurchenco and Patton, 2009; Bruckner, 2010). Indeed,
several studies have suggested that signals from assembled
laminin are critical for correct orientation of the apical–basal
axis and polarization of the cells (Eaton and Simons, 1995;
O’Brien et al., 2001; Li et al., 2003; Yu et al., 2005).
Laminins (LM) are a family of large heterotrimeric extra-
cellular matrix proteins consisting of at least 15 members
composed of combinations of ﬁve , three , and three 
subunits (Miner and Yurchenco, 2004). Most laminins as-
semble into a prototypical cruciform structure in which the
amino-terminal portion of each subunit forms the arms of
the cross and a coiled-coil of all three chains forms the stem
(Jones et al., 2000; Miner and Yurchenco, 2004; Aumailley et
al., 2005). However, a subset of laminin molecules do not
form the typical cruciform structure because their individual
subunits are “headless,” lacking the amino-terminal poly-
merization domains (Jones et al., 2000; Miner and Yurchenco,
2004; Aumailley et al., 2005). Chief among these is LM-332
(332, formerly called laminin 5, kalinin, epiligrin, and
nicein) (Miner and Yurchenco, 2004; Marinkovich, 2007).
LM-332 consists of two splice variants distinguished by the
length of their  subunits. The A subunit has a molecular
mass of approximately 190 kDa and lacks an amino-terminal
polymerization domain, whereas 3B has a size and struc-
ture closer to that of other  subunits. LM-3A32 (hereinafter
referred to as simply LM-332) is more common than LM-
3B32 and its functions are better understood (Marinkovich,
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36542007). The 3 subunit does contain a globular amino terminus
resembling the polymerization domains of other more typical
laminins, but there is conﬂicting evidence about its capacity to
participate in intermolecular associations (Cheng et al., 1997;
Odenthal et al., 2004; Yurchenco and Patton, 2009; Yurchenco
and Wadsworth, 2004). The 2 subunit completely lacks a
polymerization domain and is signiﬁcantly shorter than the 1
laminin subunit found in most typical laminins. The 3, 2,
and possibly 3 subunits are sometimes proteolytically pro-
cessed after secretion, inﬂuencing their functions (Ghosh and
Stack, 2000; Goldﬁnger et al., 2000; Aumailley et al., 2003;
Marinkovich, 2007).
LM-332 plays multiple roles in tissues. In normal skin, for
example, LM-332 is a structural molecule linking the epider-
mis to the dermis through interactions with integrin 64i n
hemidesmosomes (Jones et al., 1998). It has similar functions
in other tissues subjected to mechanical strain including
other stratiﬁed squamous epithelia, the amnion, and the
cornea (Marinkovich, 2007). Absence of LM-332 in the skin
due to mutation leads to the severe blistering disease junc-
tional epidermolysis bullosa (Masunaga, 2006). Under con-
ditions of epithelial injury, LM-332 has more dynamic func-
tions that include stimulating migration of epithelial cells
into damaged areas (Nguyen et al., 2000; Frank and Carter,
2004; Marinkovich, 2007). This process has been most exten-
sively studied in keratinocytes, where the stable adhesions
mediated through integrin 64 are modulated by addi-
tional interactions of LM-332 with integrin 31 (Hamill and
McLean, 2005; Sehgal et al., 2006; Margadant et al., 2009). The
latter localizes to focal complexes and focal adhesions where
it facilitates migration through small Rho-family GTPase
signaling and interaction with the actin cytoskeleton
(Hamelers et al., 2005). In the kidney, our laboratory ob-
served the induction of LM-332 along with the integrin 3
subunit during tubular epithelial regeneration after ischemic
injury, but the signals regulating expression and direct role
of LM-332 in the regenerative process are not understood
(Zuk and Matlin, 2002). In addition to these functions in
normal epithelia, LM-332 expression is up-regulated in a
variety of carcinomas, including those of the skin and strat-
iﬁed squamous epithelium of the oral mucosa, as well as the
epithelia of the digestive tract, respiratory tract, and cervix;
and down-regulated in others, including carcinomas of the
breast and prostate (Marinkovich, 2007). In at least some of
these cases, aberrant regulation of LM-332 expression is
correlated with tumor progression (Giannelli and Antonaci,
2000; Marinkovich, 2007; Guess and Quaranta, 2009).
Our laboratory is interested in deciphering how laminins
and laminin assembly affect the polar morphogenesis of epi-
thelial cells. We recently reported that, in addition to the net-
work-forming laminin-511, Madin-Darby canine kidney
(MDCK) cells synthesize, secrete, and deposit LM-332 only
when subconﬂuent and incompletely polarized and then cease
synthesis as soon as conﬂuence and full polarity are achieved
(Mak et al., 2006). Here, we explore the control of LM-332 syn-
thesis in MDCK cells and report that expression is transcription-
ally regulated by endogenous TGF-1 through activation and
signaling mechanisms dependent upon the epithelial barrier.
MATERIALS AND METHODS
Cell Culture
Stock cultures of MDCK cells (type II, Heidelberg isolate, passages 7–35) were
cultured in Dulbecco’s minimal essential medium (high glucose; Invitrogen,
Carlsbad, CA) supplemented with 5% (vol/vol) fetal bovine serum (FBS;
Hyclone-Fisher, Rockford, IL) and 10 mM HEPES-KOH, pH 7.3, as described
previously (Matlin et al., 1981). For studies under serum-free conditions, stock
cultures were adapted over four passages in succeedingly higher proportions
of ExCell hormone-supplemented MDCK cell medium (M3803; Sigma-Al-
drich, St. Louis, MO) containing 10 mM l-glutamine, 10 mM HEPES-KOH,
pH 7.3, and 1 antibiotic/antimycotic mixture (15240-104; Invitrogen). For
passaging of cells in serum-free medium, trypsin was neutralized with 1 mg
of soybean trypsin inhibitor per ml of trypsin (25300; Invitrogen) in ExCell.
The absence of TGF-1 in the ExCell medium was conﬁrmed by enzyme-
linked immunosorbent assay (ELISA; see Results).
For most experiments, MDCK cells were grown on Transwell permeable
supports (2.4 cm in diameter, 0.4-m pore size; 3412, Corning Life Sciences,
Lowell, MA) at a seeding density of 8  104 cells/cm2, with 1.5 ml of medium in
the upper chamber and 2.5 ml in the lower chamber. Under these conditions,
initial conﬂuence was achieved after 2–3-d culture and saturation density after 4 d.
For wound-healing experiments, conﬂuent MDCK monolayers grown on
Transwell supports were scratched multiple times with a plastic pipet tip,
taking care not to break the ﬁlter; cells were then rinsed with media and
placed in an incubator at 37°C for an additional 6 h before analysis.
Antibodies and Reagents
Antibodies used in this study are listed in Table 1.
Recombinant human TGF-1 was purchased from PeproTech (100-21,
Rocky Hill, NJ) reconstituted in 10 mM citric acid, pH 3.0, at a ﬁnal stock
concentration of 1 g/ml according to the manufacturer’s instructions, and
stored at 20°C. Under these conditions, ELISA conﬁrmed that it was com-
pletely activated (see Results). SB431542, a selective inhibitor of the TGF-
type I receptor (TR-I) kinase (activin receptor-like kinases ALK4, -5, and -7)
was purchased from Tocris Bioscience (1614; Ellisville, MO) and was stored at
a concentration of 5 M in dimethyl sulfoxide (DMSO) at 20°C. All other
chemicals were of reagent grade.
Extraction and Analysis of Endogenous Extracellular
Matrix
For analysis of endogenous extracellular matrix proteins deposited by MDCK
cells, cells were cultured on Transwell supports for various times, washed
twice with phosphate-buffered saline (PBS) without divalent cations (PBS),
and removed from the substratum by incubation with 20 mM NH4OH for
20 min at 37°C. The residual extracellular matrix attached to the support was
washed extensively with PBS and then extracted with Laemmli sample buffer
[60 mM Tris-HCl, pH 6.8, 10% sucrose (wt/vol), 2% SDS, and 0.08% bromphenol
blue], reduced with 50 mM dithiothreitol (DTT), heated at 95°C for 3 min, and
alkylated with 5 l of 0.5 M iodoacetamide per 30-l sample for 20 min at 37°C
before gel electrophoresis. Sample loading on SDS gels was normalized to culture
surface area. Separated proteins were transferred to polyvinylidene diﬂuoride
(PVDF) membranes and analyzed by Western blotting (see below).
Cell Surface Biotinylation
The polarity of the TR-I was determined by differential biotinylation of
apical and basolateral surfaces. MDCK cells grown on ﬁlters to conﬂuence
(day 4) were washed twice with PBS supplemented with 0.5 mM MgCl2 and
0.9 mM CaCl2 (PBS) and then once with biotinylation buffer (BTB; 10 mM
triethanolamine, 150 mM NaCl2, 2 mM CaCl2, and 0.5 mM MgCl2, pH 9.0)
(Gottardi et al., 1995). Either the apical or the basolateral membrane was
labeled by incubation with 0.5 mg of sulfo-NHS-biotin/ml BTB (21217; Pierce
Chemical, Rockford, IL) in PBS on ice for 30 min. Cultures were then
washed twice with DMEM followed by two washes with PBS and extracted
with radioimmunoprecipitation assay buffer (50 mM Tris, pH 7.5, 150 mM
NaCl, 1% IGEPAL-CA630, 0.5% deoxycholate, and 0.1% SDS) supplemented
with protease (11836153001; Roche Diagnostics, Indianapolis, IN) and phos-
phatase (P5726; Sigma-Aldrich) inhibitor cocktails and 10 mM glycine. Ex-
tracts were clariﬁed by brief microcentrifugation, and the protein concentra-
tion in the supernatants was determined by bicinchoninic acid assay (23227;
Pierce Chemical). Equal amounts of protein were incubated overnight with 60
l of a 1:1 (vol/vol) slurry of streptavidin-agarose beads (20347; Pierce
Chemical) in RIPA buffer. The beads were then washed three times with RIPA
buffer, and bound biotinylated proteins were solubilized by adding 2 Lae-
mmli sample buffer, reducing with DTT, and heating at 95°C for 3 min.
Samples were resolved by SDS gel electrophoresis and Western blotted with
a 1:1000 dilution of anti-TR-I antibody (see below; Table 1).
Analysis of Newly Synthesized Proteins by Metabolic
Labeling
Biosynthesis of LM-332 chains was measured by metabolic labeling of cultures
with 100 Ci of [35S]Met/Cys (NEG072; Perkin Elmer Life and Analytical Sci-
ences, Boston, MA) in DMEM without l-Met/Cys (D0422; Sigma-Aldrich) for 20
min at 37°C. Cells were then extracted with RIPA buffer supplemented with
protease and phosphatase inhibitor cocktails. Extracts were clariﬁed by brief
microcentrifugation, and supernatants were immunoprecipitated with a 1:100
dilution of anti-LM-332 (9LN5; Table 1) followed by incubation with protein
A-Trisacryl beads (20338; Pierce Chemical). Immune complexes were extracted
from the beads with 2 Laemmli sample buffer, reduced, and heated at 95°C for
3 min before gel electrophoresis and autoradiography.
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For Western blotting, SDS gels were transferred to PVDF membranes
(IPVH00010; Millipore, Billerica, MA) with a semidry apparatus (Bio-Rad
Laboratories, Hercules, CA) at 15 V for 60 min. Membranes were blocked with
5% nonfat dry milk or 3% bovine serum albumin (BSA; for detection of
phosphorylated proteins) in 10 mM Tris-Cl, pH 7.4, 150 mM NaCl, and 0.1%
Tween 20 (TBS/T), and incubated with primary antibodies for2ha troom
temperature (RT). After 3 washes with TBS/T, membranes were incubated for
an additional 1 h with a 1:1000 dilution with horseradish peroxidase-conju-
gated secondary antibodies (Table 1). Peroxidase was detected by chemilu-
minescence (170-5040; Bio-Rad Laboratories) on x-ray ﬁlms (Denville Scien-
tiﬁc, Metuchen, NJ). Bands were quantiﬁed by scanning and analyzed using
ImageJ software (http://rsbweb.nih.gov/ij/index.html).
Quantitative Real-Time Polymerase Chain Reaction (PCR)
Expressions of the 3, 3, and 2 subunits of LM-332 mRNA and the 5
subunit of LM-511 mRNA were determined by quantitative real-time reverse
transcriptase-PCR (qRT-PCR). Total RNA from cell lysates was extracted and
puriﬁed using the RNeasy kit (QIAGEN, Valencia, CA), quantiﬁed by absor-
bance measurements, and checked for integrity by formaldehyde agarose gel
electrophoresis. After DNase digestion using DNase I ampliﬁcation grade
(18068-015; Invitrogen), 900 ng of RNA was used as template for reverse-
transcription PCR (RT-PCR) using random hexamer primers and the Super-
Script III First-Strand kit (18080-400; Invitrogen). The resulting cDNAs were
treated with RNase H (18201-071; Invitrogen), and 4 l was used for qRT-PCR
using speciﬁc primers for the canine 3, 3, and 2 LM chain sequences
(QIAGEN) and a SYBR-Green master mix (QIAGEN). Ampliﬁcation was carried
out with a DNA Engine Opticon 2 thermal cycler (Bio-Rad Laboratories) using
the following cycling conditions: 95°C for 15 min, 35 cycles of 94°C for 15 s, 55°C
for 30 s, and 72°C for 40 s. Ampliﬁed PCR products corresponding to subcon-
ﬂuent cells were cloned into the TOPO 2.1 vector (K4500-01; Invitrogen), and
entire amplicon sequences including the PCR primers determined by automated
sequencing using primers ﬂanking the cloning site. Location and identity of the
amplicons in the canine genome were then veriﬁed by BLAST analysis. Serial
dilutions of plasmids containing the cloned PCR products were used to establish
a standard curve for quantiﬁcation of unknown samples by interpolation. Sam-
ples and standards were analyzed in triplicate and in duplicate, respectively, in
at least two separate experiments, and values were averaged.
Transient Expression of SMAD Constructs
Recombinant constructs of dominant-negative (DN) Smad2, Smad3, and
Smad4 cloned into the pRK5 vector (BD Biosciences Pharmingen, San Diego,
CA) were provided by Dr. Rik Derynck (University of California, San Fran-
cisco, CA; Addgene plasmids 12624, 12626, and 12628, respectively; Zhang et
al., 1996). Subconﬂuent cultures of MDCK cells were trypsinized, and 1  106
cells were transfected in suspension with 4 g of each plasmid by using an
AMAXA nucleofector (Program A-024) according to the manufacturer’s instruc-
tions (Lonza AG, Cologne, Germany). Transfection efﬁciency as estimated by
parallel transfection of a green ﬂuorescent protein expression construct was
60%. After transfection, cells where plated at standard subconﬂuent density on
permeable supports and analyzed for expression of LM-332 subunits by qRT-
PCR and Western blotting.
Immunoﬂuorescence
Cells grown on permeable supports were washed twice with PBS and ﬁxed
with 3% formaldehyde (FA) for 20 min at RT. Fixed cells were washed twice
with PBS, and unreacted FA was quenched with fresh 0.1% NaBH4/PBS
for 15 min at RT. After washing twice with PBS, cells were permeabilized
with cold 0.1% (wt/vol) Triton X-100/PBS for 4 min and again washed
twice with PBS. Nonspeciﬁc binding sites were blocked with 10% (vol/vol)
goat serum in PBS for at least1ha tR Ta n dwashed twice with PBS. At this
stage, the permeable membranes were sliced out of the plastic support and cut
into four pieces. Primary antibodies (Table 1) were diluted in blocking solution
and brieﬂy centrifuged. Cells were incubated with antibody by pipeting 100-l
drops of the diluted antibody solution onto a sheet of Paraﬁlm, placing the
membrane pieces on top of the drops with the cells upright, and then adding an
additional 100 l of dilute antibody to the top. Incubation was carried out for 2 h
at RT in a moist chamber. Membranes were then transferred to 24-well plates,
washed four times with PBS (2 min each), and then incubated with secondary
antibodies for1ha sdescribed above. After three washes with PBS, ﬁlters were
mounted in Mowiol-based mounting media (81381; Fluka, Buchs, Switzerland)
containing 0.6% (wt/vol) DABCO as antifade agent and DAPI (4,6-diamidino-
2-phenylindole; 1 g/ml) within a well formed on glass slides with dried nail
polish. Samples were observed with a 63 1.2W numerical aperture C-Apochro-
mat UV-VIS objective using an LSM510 confocal microscope Carl Zeiss, Jena,
Germany). Digital images were collected with AIM software (Carl Zeiss) and
optimized with Photoshop (Adobe Systems, Mountain View, CA).
Flow Cytometry
MDCK cells plated under subconﬂuent or conﬂuent conditions in normal growth
medium were washed twice with PBS and detached by incubation with 4 mM
EDTA, 1 mM EGTA in PBS at 37°C. Cells were centrifuged at 250  g and 4°C
and washed twice with 1% BSA/PBS. After counting, aliquots containing 5 
105 cells were incubated with 100 l of dilute anti-V3 integrin LM609 or
nonspeciﬁc mouse antibodies for 30 min on ice. Cells were washed twice with 1%
BSA/PBS, resuspended in 100 l of 1% BSA/PBS containing anti-mouse im-
munoglobulin (Ig)G-Alexa-488 (1:200), and incubated on ice for 30 min. Cells
were then washed twice with 1% BSA/PBS and resuspended in 200 lo f
PBS. The cell suspension was analyzed using a BD LSRII ﬂow cytometer at the
University of Chicago Flow Cytometry Facility (Chicago, IL).
Table 1. Antibodies
Antigen Name Species Conc (g/ml) Source/catalog no.
LM-332 9LN5 Rabbit polyclonal 4.0 M. Kocha
LM-332 4104 Rabbit polyclonal 4.0 M. Kocha
Laminin 3 Anti-Kalinin B1 Mouse monoclonal 0.5–1.25 BD Biosciences (San Diego,
CA), 610423b
Smad 2 Anti-Smad 2 Rabbit polyclonal 1.25 Invitrogen, 51-1300
Smad 3 Anti-Smad 3 Rabbit polyclonal 1.25 Invitrogen, 51-1500
Phospho-Smad 2
(Ser465/467)
Anti-phosho Smad2 A5S Rabbit monoclonal 1:1000 (supernatant) Millipore, 04-953
Phospho-Smad 3
(P-Ser423/425)
Anti-phospho Smad 3 Rabbit monoclonal 0.2–0.5 Cell Signaling Technology
(Danvers, MA), 9520
Smad 4 Anti-Smad 4 (clone B.8) Mouse monoclonal 1–8 Santa Cruz, 7966
TR-I Anti-TR-I (H-100) Rabbit polyclonal 0.2–1 Santa Cruz, 9048
TR-I Anti-TR-I Rabbit polyclonal 0.1 Cell Signaling Technology, 3712
Integrin V3 LM609 Mouse monoclonal 10 Millipore, mAb 1976Z
Tubulin (ascites) Anti-tubulin (clone TUB2.1) Mouse monoclonal (ascites) 1:10,000 Sigma-Aldrich, T4026
Mouse IgG Anti-mouse IgG-HRP Goat polyclonal 0.4 Jackson Laboratories (West
Grove, PA)
Rabbit IgG Anti-rabbit IgG-HRP Goat polyclonal 0.4 Jackson Laboratories
Mouse IgG Anti-mouse IgG-Alexa 488 Goat polyclonal 4 Invitrogen
Mouse IgG Anti-mouse IgG-Alexa 555 Goat polyclonal 4 Invitrogen
Rabbit IgG Anti-rabbit IgG-Alexa 488 Goat polyclonal 4 Invitrogen
Rabbit IgG Anti-rabbit IgG-Alexa 555 Goat polyclonal 4 Invitrogen
a University of Cologne, Germany.
b Discontinued by manufacturer.
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MDCK stock cells were plated in T-75 ﬂasks and cultured in normal growth
medium for 6 h (subconﬂuent) or 4 d (conﬂuent). The medium was then
removed, and cells were ﬁxed for 15 min at RT with 10 ml of DMEM
containing 1% formaldehyde, followed by quenching with 125 mM glycine
for 10 min. After two washes with cold PBS, the ﬁxed cells were scraped
from the dish in 5 ml of PBS containing 0.01% BSA (wt/vol) and 0.1 mM
phenylmethylsulfonyl ﬂuoride (PMSF). Samples corresponding to 2  106
cells were centrifuged at 200  g for 5 min at 4°C, resuspended in 500 lo f
“swelling buffer” (25 mM HEPES, pH 7.8, 1.5 mM MgCl2, 10 mM KCl, 0.1%
IGEPAL-CA630, 1 mM DTT, and 0.5 mM PMSF, supplemented with protease
and phosphatase inhibitor cocktails), and incubated on ice for 10 min. The
resulting cell suspension was centrifuged at 400  g for 10 min at 4°C and
resuspended in 500 l of “sonication buffer” (50 mM HEPES, pH 7.9, 140 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS,
and 0.5 mM PMSF, supplemented with protease and phosphatase inhibitor
cocktails), and sonicated using a Misonix S4000 ultrasonic processor set at
30% amplitude (microtip) and 10 cycles of 20 s “on”/40 s “off.” Subsequent
steps were based on standard EZ-ChIP kit (17-371; Millipore) procedures,
with the following modiﬁcations. Precleared chromatin:protein cross-linked
complexes were incubated with 4 g of anti-Smad4-X (Santa Cruz Biotech-
nology, Santa Cruz, CA; Table 1), anti-RNA polymerase II, or control IgG
overnight at 4°C on a rotary shaker. Cross-linking of eluted chromatin:protein
complexes was reversed by incubation for 4.5 h at 65°C in a water bath and
treated with proteinase K. The resulting free, fragmented chromatin was
column puriﬁed, and 8 l of the eluted DNA was ampliﬁed by touchdown-
PCR (Korbie and Mattick, 2008) with a manual hot-start (using the primers
described in Table 2) as follows: 95°C for 1.5 min followed by addition of 1 l
of Amplitaq polymerase (Invitrogen); 1.5 min at 95°C, ampliﬁcation phase 1
consisting of 10 cycles: 95°C for 30 s, 64°C for 45 s (decreasing the annealing
temperature 1°C every cycle; ﬁnal temperature 54°C), and 72°C for 60 s;
ampliﬁcation phase 2 consisting of 25 cycles of 95°C for 30 s, 54 and 72°C for
60 s; and ﬁnally a termination phase at 72°C for 5 min. Ten microliters of the
PCR products was mixed with 6 loading sample buffer, resolved by 2%
agarose gel electrophoresis and analyzed using a GelDoc (Bio-Rad Laborato-
ries). Positive samples were sequenced at the University of Chicago Cancer
Research Center DNA Sequencing Facility.
Treatment with Blocking Antibodies and Peptides
Cells grown in ExCell were detached and 1  106 cell aliquots were preincu-
bated with 1 g of LM609 (anti-V3 integrin), nTGF-1 (neutralizing active
TGF-1), or nonspeciﬁc mouse IgG in 300 l of ExCell medium for 30 min at
RT on a rotary shaker. Cells were plated on Transwell permeable supports as
described above in the presence of an additional 1 g of antibody in both the
upper and lower chambers and incubated at 37°C. For peptide treatment, cells
were preincubated as described above in the presence of 1 mM GRGDS
peptide (RGD; 03-34-0027; EMD Chemicals, Gibbstown, NJ) or RGES (RGE;
A5686; Sigma-Aldrich) and then for the entire experiment.
Measurement of TGF-1 Levels
The concentration of active and total TGF-1 in culture media was deter-
mined by sandwich ELISA using the ELISA Emax kit purchased from Promega
(G7590; Madison, WI) in 96-well enzyme immunoassay/radioimmunoassay
high-binding plates (3590; Corning Life Sciences) according to the manufac-
turer’s instructions with the following modiﬁcations. Samples of culture
media were collected in sterile tubes, brieﬂy microcentrifuged, passed
through a 0.45-m ﬁlter to remove cell debris, and snap-frozen until analysis.
The day of the assay, samples were divided in two, and one half was acidiﬁed
with HCl to pH 3.0 for 30 min at RT to activate TGF-1 and then neutralized
to pH 7.5–8.0 with NaOH. Samples were then diluted 1:2–1:4 in the pro-
vided sample buffer and incubated for2ha tR Twith gentle shaking. The
remainder of the assay was performed according to the ELISA kit protocol.
Differential measurement of active and total TGF-1 was accomplished by
analyzing samples before and after the activating acidiﬁcation, as this kit uses
an antibody speciﬁc for the active form of TGF-1. The amount of latent
TGF-1 was determined by subtracting the active fraction from the total
fraction. Plates were read in a SpectraMax M5 plate reader (Molecular De-
vices, Sunnyvale, CA) at 450 nm.
Statistical Analysis
Statistical signiﬁcance was determined by one-way analysis of variance with
Tukey’s post hoc test for multiple comparisons, and a two-tailed unpaired t
Figure 1. Laminin-332 (LM-332) expression is regulated as a func-
tion of conﬂuence. (A) LM-332 deposition only occurs in subconﬂu-
ent cells. Subconﬂuent (day 1) or conﬂuent (day 4) MDCK cells
cultured on 0.4-m Transwell supports were immunostained for
LM-332 with an anti-3 subunit mAb (green). Confocal sections
corresponding to the basal plane (deposited extracellular matrix
[ECM]) are shown. Bar, 10 m. (B) Signiﬁcant amounts of LM-332
are deposited into the substratum only in subconﬂuent (day 1)
cultures. Cells plated on Transwell supports were removed by
treatment with 20 mM NH4OH at the indicated time points (days
1–7). Deposited ECM proteins were extracted, resolved by SDS-
polyacrylamide gel electrophoresis and Western-blotted for LM-332
with an anti-3 mAb. (C) Laminin 3 and 2 subunit expression is
transcriptionally regulated as a function of cell conﬂuence. RNA
from Transwell cultures was isolated at different time points (days
1–4) and analyzed by qRT-PCR using canine-speciﬁc primers. Inset,
qRT-PCR for the 5 subunit of LM-511 (LM-5). The histograms
represent the average abundance of mRNAs from three indepen-
dent experiments expressed in picograms  SD. **p  0.01 or *p 
0.05 relative to day 1 (d1) levels.
Table 2. Oligonucleotides used for PCR and qRT-PCR
LM 3-Fwda & Revb QuantiTect Primer Assay QT01465975*
LM 3-Fwd & Rev QuantiTect Primer Assay QT01116472*
LM 2-Fwd & Rev QuantiTect Primer Assay QT00898541*
LM 5-Fwd & Rev QuantiTect Primer Assay QT01450638*
SBE-Fwd 5-ATG TAG GGA AAC TTC AGA CAT
GC-3
SBE-Rev 5-ACT TCC TAC CTG ACA TGA GTC
ACC-3
GAPDHc-Fwd 5-ACA GTC AAG GCT GAG AAC G-3
GAPDH-Rev 5-GGC ATT GCT GAC AAT CTT G-3
* Qiagen.
a Forward.
b Reverse.
c Glyceraldehyde-3-phosphate dehydrogenase.
Autocrine Regulation of Laminin-332 by TGF-1
Vol. 21, November 1, 2010 3657test for single comparisons using the Instat application (GraphPad Software,
San Diego, CA). P values 0.05 were considered signiﬁcant.
RESULTS
LM-332 Expression Is Transcriptionally Regulated in
MDCK Cells as a Function of Conﬂuence
Previous results from our laboratory demonstrated that
MDCK cell cultures synthesized and deposited LM-332 only
when subconﬂuent, with little or no synthesis occurring
once conﬂuence was achieved (Mak et al., 2006). To conﬁrm
and extend these ﬁndings, we examined MDCK cells cul-
tured on Transwell permeable supports under conditions in
which cultures are subconﬂuent 1 d after plating and reach
full conﬂuence after 3–4 d of growth.
As shown in Figure 1, LM-332 was visible in a basal
optical section by confocal immunoﬂuorescence microscopy
only in a subconﬂuent (day 1) culture but not in a conﬂuent
(day 4) culture (Figure 1A). Similarly, LM-332 (as detected
by Western blotting with an antibody against the 3 sub-
unit) was deposited onto the permeable support in signiﬁ-
cant amounts at day 1 of culture but was present in dimin-
ishing amounts at day 4 and, to an even lesser extent, at day
7, suggesting that not only was secretion and deposition of
LM-332 reduced as conﬂuence was achieved but also that
any residual LM-332 was removed (Figure 1B).
To determine whether decreased production of LM-332
was regulated at the transcriptional level, RNA extracted
from cultures at different degrees of conﬂuence was exam-
ined by qRT-PCR using primers speciﬁc for the canine 3,
3, and 2 laminin subunit mRNAs. As shown in Figure 1C,
mRNAs for all three subunits were expressed at day 1, with
levels of 3 mRNA the highest. By day 2, however, amounts
of both the 3 and 2 mRNAs had signiﬁcantly declined and
remained low through day 4. Curiously, amounts of the 3
mRNA, as well as the 5 subunit mRNA of LM-511, continued
to be produced at approximately the same level independently
of conﬂuence, These observations not only demonstrated that
expression of LM-332 is transcriptionally regulated as a func-
tion of conﬂuence but conﬁrm previous protein biosynthesis
data indicating that only the 3 and 2 subunits are down-
regulated as conﬂuence is achieved, whereas the 3 subunit
continues to be synthesized (Mak et al., 2006).
Exogenous TGF-1 Stimulates LM-332 Expression in
Conﬂuent Cultures
Analysis of the promoter region of the human laminin
3A gene identiﬁed previously several transcriptional
regulatory elements including three AP1 (Fra2/JunD)
binding sites, a TGF- response element, two KLF4 sites,
and a noncanonical E-box that binds USF-1 (Virolle et al.,
Figure 2. Exogenous active TGF-1 is sufﬁcient
to induce LM-332 expression in conﬂuent cells.
(A) TGF-1 induces transcription of the laminin
3 subunit gene. Conﬂuent MDCK cells un-
treated (control) or treated with 5 ng/ml active
TGF-1f o r6hi nserum-free medium (TGF-
1) were collected and analyzed for laminin 3
subunit mRNA by q-RT-PCR. **p  0.0011 (B)
TGF-1 induces LM-332 protein synthesis. i,
untreated control (control) or TGF-1-treated
(TGF-1) conﬂuent cultures were metaboli-
cally labeled with [35S]Met/Cys for 20 min and
extracted with RIPA buffer. The extracts were
immunoprecipitated with a polyclonal antibody
against LM-332, and the immunoprecipitates
were resolved by SDS-polyacrylamide gel elec-
trophoresis and detected by autoradiography.
The graph represents the intensities of the 3
bands in this experiment. ii, equal amounts of
total protein from RIPA lysates were analyzed by
Western blot for LM-332 using a mAb against the
3 subunit with immunoblotting for tubulin as
loading control. (C) Confocal immunoﬂuores-
cence localization of LM-332 after TGF-1 treat-
ment. Subconﬂuent and conﬂuent MDCK cell
cultures without added exogenous TGF-1, and
TGF-1-treated conﬂuent MDCK cells were im-
munostained with a polyclonal antibody against
LM-332 (red) and optical sections of a mid/basal
plane visualized. Nuclei were stained with DAPI
(blue). Bar, 10 m. (D) Transepithelial resistance
of MDCK cells is not affected by TGF-1 treat-
ment. Transepithelial electrical resistance of con-
ﬂuent MDCK cultures grown on Transwell sup-
ports in either the absence or presence of
exogenous active TGF-1 was measured with a
Millicell-ERS device. The experiment was re-
peated four times, and the average is shown. n.s.,
not statistically signiﬁcant, p  0.1743.
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los et al., 2008). Of these, the TGF- response element
stood out because TGF- is well known as a regulator of
extracellular matrix gene expression and elevated levels
of TGF- have been observed in the kidney in response to
ischemic injury, conditions where expression of LM-332 is
also known to be increased (Basile et al., 1998; Ledbetter et
al., 2000).
To test the involvement of TGF-1 in regulation of LM-332
production in MDCK cells, exogenous activated TGF-1 was
added both apically and basolaterally to conﬂuent (day 4)
cultures of MDCK cells that normally do not express LM-332
(Figure 1). As illustrated in Figure 2A, addition of TGF-1
for 6 h stimulated transcription of mRNA for the 3 subunit.
In addition, increased synthesis of LM-332 was also evident
in similarly treated cultures when analyzed either by meta-
bolic-labeling and immunoprecipitation or Western blotting
(Figure 2B). These ﬁndings were further supported by de-
tection of LM-332 in treated cells by immunoﬂuorescence
(Figure 2C). Treatment with exogenous TGF-1 did not
compromise the epithelial barrier, as determined by mea-
surement of transepithelial resistance (Figure 2D). Thus,
under conditions in which MDCK cells do not normally
express LM-332, TGF-1 treatment induces LM-332
mRNA transcription and protein synthesis, suggesting a
possible physiological role for TGF-1 in the regulation of
LM-332 expression.
Activin-like Kinase Activity of TR-I Is Required for
LM-332 Expression
TGF- normally signals through type I and II receptors that
are believed to form a heterotetramer on the cell surface
when ligated (Wrana et al., 2008). In MDCK cells, the TR-I
receptor was expressed on the basolateral surface of conﬂu-
ent cultures, as determined by domain-selective biotinyla-
tion and Western blotting (Figure 3A), conﬁrming previous
results (Murphy et al., 2004). To ascertain whether this re-
ceptor is used by MDCK cells in the expression of LM-332,
cells were preincubated with SB431542, a selective inhibitor
of activin receptor-like kinase (ALK) superfamily members,
including TR-I (Inman et al., 2002), for 30 min before addi-
tion of exogenous activated TGF-1f o r6ht oboth the apical
and basolateral chambers of a conﬂuent Transwell culture of
MDCK cells. As shown in Figure 3B, transcription of the
laminin 3 gene, as determined by qRT-PCR, and synthesis
of LM-332, as determined by immunoﬂuorescence and
Western blotting, was nearly abolished in samples treated
with exogenous TGF-1 and the TR-I receptor inhibitor
relative to control cultures treated only with TGF-1 and
vehicle (Figure 3, B–D). Furthermore, when subconﬂuent
cultures of MDCK cells, which synthesize LM-332 in the
absence of exogenous TGF-1 stimulation, were treated with
the inhibitor under the same conditions, LM-332 synthesis
was signiﬁcantly diminished (Figure 3E). Overall, these re-
sults strongly suggest that the TGF-1 receptor TR-I is
Figure 3. Kinase activity of the TGF- receptor
type I (TR-I) is required for LM-332 expression.
(A) TR-I is localized basolaterally in polarized
MDCK cells. Conﬂuent cultures of MDCK cells
grown on permeable supports were biotinylated
either apically (AP) or basolaterally (BL). Biotinyl-
ated proteins were captured on streptavidin-conju-
gated beads and immunoblotted with anti-TR-I
antibodies. The unbound protein fraction was used
for immunoblotting with an mAb against tubulin
as loading control. These experiments were re-
peated twice with similar results. (B) Inhibition of
TR-I signaling abolishes laminin 3 subunit
mRNA expression. Conﬂuent MDCK cells were
pretreated with DMSO (control) or with 5 M
TR-I kinase activity inhibitor SB431542 (SB43)
for 30 min. Then, cells were either incubated with
or without exogenous TGF-1 for 6 h and analyzed
for laminin 3 subunit mRNA expression by qRT-
PCR. n.s., not statistically signiﬁcant; ***p  0.001;
**p  0.01 (C) LM-332 protein expression is also
diminished after blocking TR-I signaling in TGF-
1–treated conﬂuent MDCK cells. Conﬂuent cul-
tures of MDCK cells untreated or pretreated with
SB431542 were then incubated with or without ex-
ogenous TGF-1 for 6 h, and LM-332 expression
was detected by immunoﬂuorescence. Control/
conﬂuent, no TGF-1 or SB431542; control/conﬂu-
ent  TGF-1, treated with TGF-1 but no
SB431542; SB431452/conﬂuentTGF-1, treated
with both TGF-1 and SB431452. Bar, 10 m. (D)
Production of LM-332 was examined by Western
blotting of MDCK cell extracts using an anti-3
subunit monoclonal from cultures treated as de-
scribed in C. SB43, treated with SB431452. (E) LM-
332 expression is also dependent on TR-I signal-
ing in subconﬂuent cells. Subconﬂuent MDCK cell
cultures without addition of exogenous TGF-1
were incubated with or without SB431452 (SB43)
for 18 h, and extracts were Western blotted for the
3 subunit of LM-332.
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MDCK cells.
TGF-1 Signaling through Smad2 and Smad 4 Is
Responsible for Stimulating LM-332 Expression
The major signaling pathway downstream of TGF-1 and its
type I and II receptors involves Smad proteins (Schmierer
and Hill, 2007; Schilling et al., 2008). However, TGF-1 and
its receptors are also known to signal through a variety of
Rho-family small GTPases, several mitogen-activated pro-
tein kinase pathways, including those leading to extracellu-
lar signal-regulated kinase, p38, and c-Jun NH2-terminal
kinase, and PP2A/p70S6K (Schilling et al., 2008). It was there-
fore important to determine whether Smads are the primary
signal transducers involved in TGF-1–mediated LM-332
expression. To accomplish this, Smad phosphorylation,
complex formation, and nuclear localization were examined.
Ligated TGF-1 type I and II receptors phosphorylate the
so-called “receptor-activated” or R-Smads Smad 2 and -3. As
shown in Figure 4A, phospho-Smad2 was detected in sub-
conﬂuent MDCK cell cultures expressing LM-332 but not in
conﬂuent cultures. Stimulation of conﬂuent cultures with
exogenous activated TGF-1–stimulated phosphorylation of
Smad2, whereas inhibition of TR-I with SB431542 blocked
this phosphorylation. In contrast, Smad3 phosphorylation
was low in subconﬂuent cultures, and baseline levels of
Smad3 phosphorylation were only modestly affected by ex-
ogenous TGF-1 and the inhibitor of TR-I in conﬂuent
cultures (Figure 4A), suggesting that Smad2 but not Smad3
was involved in TGF-1 signaling in MDCK cells under
these conditions.
Activation of transcription by Smads requires formation
of a complex between a phosphorylated R-Smad, such as
Smad2 and Smad3, and Smad4, followed by translocation of
the complex into the nucleus where it interacts with the
promoter region of target genes. As illustrated in Figure 4B,
phospho-Smad2 was almost undetectable in conﬂuent
MDCK cell cultures by immunoﬂuorescence but increased
in intensity and concentrated in nuclei upon stimulation
with exogenous TGF-1. Smad4 was also localized in nuclei
in subconﬂuent cultures of MDCK cells known to express
LM-332 and concentrated in nuclei in conﬂuent cultures that
had been treated with exogenous TGF-1 (Figure 4C). This
localization was signiﬁcantly reduced upon preincubation
with the TR-I inhibitor (Figure 4C).
To determine whether phospho-Smad2 and Smad4 inter-
acted after TGF-1 stimulation, cell extracts were immuno-
precipitated with anti-Smad4 followed by Western blotting
Figure 4. Phospho-Smad2 and Smad4 regulate LM 3
subunit gene transcription. (A) Differential phosphorylation
of Smads. Subconﬂuent (Subcﬂ.) or conﬂuent cultures either
untreated (control) or treated with 5 ng/ml TGF-1f o r6hi n
the absence or presence of the TR-I inhibitor SB431542
(TGF-1o r TGF-1SB43, respectively) were analyzed
by Western blotting for phospho-Smad2 (P-Smad2), total
Smad2, P-Smad3, and total Smad3. (B) Phospho-Smad2 is
localized to the nuclei after TGF-1 treatment in conﬂuent
cells. Untreated (control) or TGF-1–treated conﬂuent cells
(TGF-1) were stained with antibodies against P-Smad2
(red) and LM-332 (3 subunit; green) and analyzed by con-
focal ﬂuorescence microscopy. Nuclear staining with DAPI,
blue. Bar, 10 m. (C) Smad 4 is also localized to the nuclei in
subconﬂuent and TGF-1–treated conﬂuent cells. Subconﬂu-
ent MDCK cell cultures without added exogenous TGF-1
and conﬂuent cultures either untreated (control) or treated
with of TGF-1 in the presence or absence of SB431542 (SB)
were stained with antibodies against Smad4 (green) and an-
alyzed by confocal ﬂuorescence microscopy. Nuclear stain-
ing with DAPI, blue. Bar, 10 m. (D) Phosho-Smad2 and
Smad4 form a complex dependent on TR-I signaling. Con-
ﬂuentculturestreatedwithTGF-1toinduceLM-332expres-
sion in the absence or presence of the TR-I inhibitor
SB431542 (TGF or TGFSB43, respectively) were ex-
tracted in RIPA buffer. Extracts were immunoprecipitated
with an anti-Smad4 antibody (mouse) and Western blotted
with anti-P-Smad2 antibody (rabbit). (E) P-Smad2 and
Smad4 also form a complex in subconﬂuent cells. Extracts of
subconﬂuent MDCK cell cultures without added exogenous
TGF-1 were immunoprecipitated with a control IgG (mock)
or with an anti-Smad4 antibody (mouse), and Western blot-
ted for P-Smad2 (rabbit). (F) DN Smad2 and Smad4, but not
Smad3, impairs 3 subunit transcription in subconﬂuent cul-
tures. Subconﬂuent MDCK cell cultures were transiently
transfected with DN-Smad2, DN-Smad3, or DN-Smad4, and
3 subunit mRNA expression was analyzed by qRT-PCR
after 24 h. **p  0.05; ***p  0.001 (G) Smad4 binds to an
Smad binding element in the 3 subunit gene promoter.
Subconﬂuent (6 h) or conﬂuent (4 d) MDCK cell extracts
were subjected to ChIP with anti-Smad4, RNA-polymerase
II, or nonspeciﬁc antibodies (IgG). Enrichment of the SBE in
the immunoprecipitated chromatin was determined by
touchdown-PCR using primers speciﬁc for the 3 subunit
promoter. Products were resolved by agarose gel electro-
phoresis (negative staining is shown) and compared with
whole chromatin lysates (input).
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and phospho-Smad2 coimmunoprecipitated upon stimula-
tion of a conﬂuent culture with TGF-1, and this association
was abolished when the culture was pretreated with the
TR-I inhibitor. Similarly, coimmunoprecipitated phospho-
Smad2 and Smad4 were also evident in subconﬂuent MDCK
cells in the absence of exogenous TGF-1 (Figure 4E), con-
sistent with a role for Smad2/Smad4 signaling in LM-332
production in subconﬂuent cultures.
As a ﬁnal proof that Smad signaling was responsible for
TGF-1–mediated LM-332 expression, dominant-negative
constructs of Smad2, Smad3, and Smad4 were transiently
expressed in MDCK cells. After culturing the transfected
cells overnight under subconﬂuent conditions, RNA was
extracted and the amount of laminin 3 transcripts esti-
mated by qRT-PCR. As shown in Figure 4F, transfection
with Smad2 and Smad4 dominant-negative constructs re-
duced the levels of laminin 3 mRNA relative to controls,
whereas transfection with dominant-negative Smad3 had no
effect.
Previous studies have demonstrated that TGF-1 activa-
tion of laminin 3 expression in keratinocytes and carci-
noma cell lines occurs via binding of Smad4 to a Smad
binding element (SBE) in the 3 gene promoter. To conﬁrm
that this is also the case in MDCK cells, ChIP was carried out
with an antibody against Smad4 and PCR primers demar-
cating a 246-nucleotide upstream region of the canine lami-
nin 3 gene. As shown in Figure 4G, ChIP from chromatin
Figure 5. MDCK cells constitutively secrete endogenous TGF-1 but only activate it
under subconﬂuent conditions. (A) Latent TGF-1 is activated only in subconﬂuent cells.
Subconﬂuent and conﬂuent cultures were grown in normal growth medium (containing
5% FBS) and the conditioned media were analyzed for total and active TGF-1b y
sandwich ELISA. **p  0.01 (B) Cells grown in ExCell also express LM-332 only when
subconﬂuent. MDCK cells were grown in ExCell, a deﬁned serum-free growth media, on
Transwell supports for 1 d (subconﬂuent) or 4 d (conﬂuent); ﬁxed; stained; and analyzed
for LM-332 expression (red) by confocal immunoﬂuorescence microscopy; nuclei were
stained with DAPI (blue). Bar, 10 m. (C) MDCK cells constitutively secrete latent
TGF-1. Conditioned media of cells grown in ExCell and normal serum-containing
growth medium (GM) were analyzed for total and active TGF-1 using sandwich ELISA.
***p  0.001 (D) Conﬂuent MDCK cells secrete latent TGF-1 apically. MDCK cells were
grown in ExCell serum-free medium on Transwell supports for4dt oachieve full
apicobasal polarization. Conditioned medium from either the apical or basal compart-
ments was analyzed for total TGF-1 by sandwich ELISA. *p  0.05 (E) Neutralization of
endogenous active TGF-1 reduces LM 3 subunit expression. Subconﬂuent MDCK cell cultures grown in ExCell in the presence of 1 go f
neutralizing antibody against active TGF-1 (nTGF-1) or IgG as negative control were analyzed for 3 subunit mRNA levels by qRT-PCR.
*p  0.0143.
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and immunoprecipitated with anti-Smad4 or anti-RNA-
polymerase II yields an appropriately-sized PCR product,
whereas chromatin from conﬂuent cells not producing LM-
332 and nonspeciﬁc IgG controls do not. Sequencing of the
PCR product conﬁrmed that the region containing the SBE
was immunoprecipitated and ampliﬁed (data not shown).
Together, the results of this experiment and the analysis of
Smad phosphorylation, nuclear localization, complex forma-
tion, and dominant-negative Smad expression strongly sup-
port the central involvement of Smad2 and Smad4 in TGF-
1–stimulated expression of LM-332.
MDCK Cells Constitutively Secrete Latent TGF-1 and
Activate It Only under Subconﬂuent Conditions
In all previous experiments, MDCK cells were cultured in
medium containing 5% FBS that presumably contains TGF-
1. Furthermore, this serum-containing medium was
present in both the apical and basolateral chambers of Trans-
well cultures. Despite this, TGF-1–stimulated expression of
LM-332 only occurred under subconﬂuent conditions or
when exogenous activated TGF-1 was added to conﬂuent
cultures. TGF- is an unusual growth factor in that it is
secreted in an inactive or “latent” form and must be acti-
vated to enable its binding to cell surface receptors and
elicitation of downstream effects. For this reason, it seemed
as though TGF-1 contributed from the serum would have
to be differentially activated in MDCK cells as a function of
conﬂuence if it was indeed the physiological stimulus of
LM-332 expression.
To test this, serum-containing growth medium and con-
ditioned medium from subconﬂuent and conﬂuent cultures
were analyzed by an ELISA capable of distinguishing active
from inactive TGF-1. As shown in Figure 5, TGF-1i s
indeed present in serum-containing MDCK cell growth me-
dium but is almost completely inactive (Figure 5A). In con-
trast, conditioned medium taken from subconﬂuent cultures
had a signiﬁcant fraction of activated TGF-1, whereas the
medium from conﬂuent cultures only contained inactive
TGF-1 (Figure 5A).
Although it was conceivable that MDCK cells depended
upon exogenous TGF-1 from serum to stimulate LM-332
expression, it was also possible that TGF-1 was endog-
enously produced. To determine this, MDCK cells were
grown in a commercial hormone-supplemented serum-free
medium (ExCell), and production of LM-332 was analyzed.
As shown in Figure 5B, subconﬂuent but not conﬂuent
MDCK cell cultures grown in ExCell in the absence of serum
Figure 6. V3 integrins regulate TGF-1 activation and LM-332 expression. (A) MDCK cells express integrin V3 on the cell surface.
Subconﬂuent and conﬂuent cells were incubated with monoclonal anti-V3 (LM609) or mouse IgG (control), and analyzed by ﬂow
cytometry to determine cell surface expression levels. (B) Integrin V3 is localized to the apical and lateral plasma membrane in
subconﬂuent cells but is basolaterally polarized in conﬂuent cultures of MDCK cells. Subconﬂuent and conﬂuent (polarized) MDCK cell
cultures grown in ExCell on Transwell supports were stained for V3 integrins with the LM609 (green) and analyzed by confocal
microscopy. XZ stacks (lateral views) are shown. Nuclei, blue. Bar, 10 m. (C) Integrin V3 participates in TGF-1 activation. MDCK cells
were pretreated with a nonspeciﬁc antibody (IgG) or anti-V3 function blocking antibody (LM609) for 30 min and then grown for 18 h in
ExCell (subconﬂuent cultures). The conditioned media was analyzed by sandwich ELISA to determine TGF-1 activation. IgG, nonspeciﬁc
immunoglobulin. n.s., not statistically signiﬁcant; *p  0.05 (D) Inhibition of V3 integrin prevents LM-332 expression. Subconﬂuent MDCK
cell cultures grown on Transwell supports in ExCell were pretreated with either anti-V3 function blocking antibody (LM609) or a
nonspeciﬁc antibody (IgG), and after 18 h LM-332 (green) was detected by confocal immunoﬂuorescence. The dotted line indicates the edge
of an “island” of cells. Nuclei, blue. Bar, 10 m.
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analyzed by ELISA, fresh ExCell medium completely lacked
TGF-1. However, conditioned ExCell medium from sub-
conﬂuent and conﬂuent cultures contained signiﬁcant
amounts of latent TGF-1 presumably synthesized by
MDCK cells (Figure 5C). Furthermore, because the medium
analyzed was changed every day, and thus in contact with
cells for not 	1 d, these results suggested that synthesis of
TGF-1 by MDCK cells was not regulated as a function of
conﬂuence but was constitutive at all stages of culture
growth. More importantly, 25% of endogenous TGF-1
was activated in medium from subconﬂuent cultures,
whereas much less was activated in conditioned medium
from conﬂuent cultures (Figure 5C). Because conﬂuent cul-
tures of MDCK cells are fully polarized, with apical and
basal chambers of the Transwell supports isolated by tight
junctions between the cells, it was of interest to determine
whether endogenous TGF-1 was secreted in a polarized
manner. Indeed, ELISA analysis of total TGF-1 in apical
and basal media from conﬂuent ExCell cultures indicated
that most TGF-1 produced by MDCK cells was secreted
into the apical chamber, conﬁrming previous observations
from others (Figure 5D; Murphy et al., 2004). As a ﬁnal
conﬁrmation that endogenous TGF-1 was capable of stim-
ulating LM-332 expression, subconﬂuent MDCK cells grown
in ExCell were preincubated with a neutralizing TGF-1
antibody (nTGF-1) that speciﬁcally blocks the function of
the active form, and laminin 3 mRNA expression was
analyzed by qRT-PCR. As shown in Figure 5E, treatment
with nTGF-1, but not with a control IgG, signiﬁcantly
reduced 3 chain mRNA transcription, proving that endog-
enous active TGF-1 is required for laminin 3 expression in
MDCK cells.
Together, the results of the experiments described in this
section demonstrate that MDCK cells constitutively synthe-
size and secrete TGF-1 at all stages of conﬂuence but only
activate it in subconﬂuent cultures. Furthermore, this endog-
enous activated TGF-1 is the physiological stimulator of
laminin 3 expression.
MDCK Cells Use Integrin V3 to Activate TGF-1i n
Subconﬂuent Cultures
The latency of TGF-1 is due to its continued association
with its propeptide (latency associated peptide [LAP]) after
secretion. Activation has been postulated to occur through a
variety of mechanisms including controlled proteolysis of
LAP and possibly the latent TGF- binding protein (LTBP)
by plasmin or other proteases including matrix metalloen-
doproteases (MMPs), interaction with thrombospondin, in-
tegrin binding, or some combination of these mechanisms
(Dabovic and Rifkin, 2008). In particular, the LAP of TGF-1
contains an integrin RGD binding site, and integrins such as
V6 have been implicated in TGF- activation (Dabovic
and Rifkin, 2008). Because MDCK cells express integrin
V3, an RGD-binding integrin (Schoenenberger et al.,
1994), and possibly other V containing integrins (Tera ¨-
va ¨inen and Manninen, University of Oulu, Oulu, Finland;
personal communication), it was conceivable that this recep-
tor was playing a role in TGF-1 activation.
Initially, expression of V3 was conﬁrmed by ﬂow cy-
tometry and immunoﬂuorescence using the LM609 mono-
clonal antibody (mAb) speciﬁc for the integrin. As shown in
Figure 6A, ﬂow cytometry detected V3 on both subcon-
ﬂuent and conﬂuent cells, although levels on conﬂuent cells
were slightly reduced (4.7-fold vs. 3.6-fold relative to
controls). Expression was also evident in orthogonal (xz)
sections of subconﬂuent and conﬂuent cultures generated by
confocal immunoﬂuorescence microscopy. As expected,
V3 was localized to the basolateral plasma membrane in
conﬂuent cultures, as reported previously (Schoenenberger
et al., 1994), but in subconﬂuent cultures is also present on
the apical domain (Figure 6B).
The LM609 antibody is capable of blocking cell adhesion
to vitronectin and ﬁbronectin. To determine whether it also
had an effect on TGF-1 activation in MDCK cells, subcon-
ﬂuent ExCell cultures were pretreated with LM609 or a
nonspeciﬁc IgG for 30 min, and TGF-1 activation was de-
termined by ELISA after 18 h. Under these conditions,
LM609 dramatically inhibited TGF-1 activation but not
secretion (Figure 6C). To ﬁnd out whether LM609 also
blocked expression of LM-332, MDCK cells were cultured in
ExCell in the presence of LM609 or control IgG. As shown in
Figure 7. TGF-1 activation and LM-332 expression in subconﬂu-
ent MDCK cells is regulated by RGD. (A) The RGD peptide inhibits
TGF-1 activation. Subconﬂuent MDCK cells were grown in ExCell
for 18 h in the absence (Subcnf.) or presence of either RGD or RGE
peptides (1 mM). The conditioned media were collected and ana-
lyzed for TGF-1 activation by ELISA. Histograms represent the
ratio of active versus total TGF-1. **p  0.01 (B) RGD inhibits
LM-332 expression. Cell cultures corresponding to A were immu-
nostained for LM-332 with a polyclonal antibody (green). Actin, red;
nuclei, blue. The numbers indicate relative units of ﬂuorescence
(SD) for the green channel (LM-332). Bar, 10 m.
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almost completely abrogated LM-332 expression.
Because V3 integrin can bind LAP, which is an RGD-
containing protein (Ludbrook et al., 2003), we next treated
subconﬂuent MDCK cell cultures with either soluble RGD or
RGE peptides and measured TGF-1 activation and LM-332
production. As shown in Figure 7A, the presence of soluble
RGD, but not RGE, signiﬁcantly reduced TGF-1 activation.
In a similar way, LM-332 expression was greatly diminished
as shown by immunoﬂuorescence (Figure 7B).
Overall, these experiments demonstrate that the RGD-
binding integrin V3 is essential for the activation of
TGF-1 in MDCK cells and conﬁrm that this activation is
required for expression of LM-332 in subconﬂuent cultures.
Mechanical Wounding of Conﬂuent MDCK Cell Cultures
Is Sufﬁcient to Activate TGF-1 and Stimulate LM-332
Expression
Previous results demonstrated that TGF-1 activation and con-
sequent LM-332 expression occurs exclusively in subconﬂuent
cultures of MDCK cells. Subconﬂuence is an in vitro phenom-
enon created by plating cells at low density. Epithelia in vivo
are rendered “subconﬂuent” by wounding or injury that opens
gaps in the continuous epithelium. To determine whether
wounding was equivalent to subconﬂuence with regard to
TGF-1 activation and LM-332 expression, conﬂuent cultures of
MDCK cells were mechanically wounded by scraping multiple
times with a pipette tip and analyzed. As shown in Figure 8,
wounding of conﬂuent cultures produced both an apparent
Figure 8. Wounded conﬂuent MDCK monolayers express LM-332. (A) Wounded epithelial monolayers activate TGF-1. Conditioned media
from a conﬂuent MDCK cell culture (control) and a culture wounded by scraping with a pipette tip were analyzed by sandwich ELISA for total
and active TGF-1. **p  0.01 (B) LM-332 expression is localized to the cells close to the wound edge. A conﬂuent MDCK cell monolayer (control)
and a culture injured by scraping (Wound) were analyzed after 6 h for LM-332 expression (green; left) or P-Smad2 (green/arrows; right). F-actin,
red; nuclei, blue. Bar, 25 m. (C) LM-332 synthesis is up-regulated in wounded cultures. Conﬂuent MDCK cell monolayers (Ctrl) or wounded
cultures (Wnd) were metabolically labeled with [35S]Met/Cys for 20 min 6 h after wounding, and synthesized LM-332 was analyzed by
immunoprecipitation. Autoradiography revealed increased levels of 3, 3, and 2 subunit synthesis in wounded monolayers compared with the
unwounded control. The numbers between parentheses indicate fold-increase in band intensity compared with the control. Note that 3 and 2
subunits show a similar fold-increase, consistent with coregulation of the 3 and 2 mRNAs. (D) Blocking V3 integrin with LM609 or RGD
prevents TGF-1 activation and LM-3 mRNA expression. Conﬂuent MDCK cell monolayers were treated with either anti-V3 function blocking
antibody (LM609), a nonspeciﬁc antibody (IgG), RGD or RGE peptides in ExCell. After 6 h, the conditioned media were analyzed for TGF-1
activation (gray bars), and the cells were analyzed for LM-3 mRNA expression by qRT-PCR (black bars). n.s., not statistically signiﬁcant compared
with “wound”; *p  0.05; **p  0.01 (E) Wounded MDCK monolayers treated as described in D were analyzed by immunoﬂuorescence for LM-332
with a polyclonal antibody (green). F-actin, red; nuclei, blue. Bar, 25 m.
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as signiﬁcantly more activation (Figure 8A). Furthermore, in-
creased LM-332 synthesis and phospho-Smad2 were evident
by immunoﬂuorescence at the wound edge (Figure 7B) and by
immunoprecipitation of LM-332 after metabolic-labeling of the
wounded culture (Figure 7C), suggesting that expression of
LM-332 is regulated in this situation in a manner identical to
that established for subconﬂuent cultures.
To determine whether the LM609 antibody or RGD pep-
tides were also able to impair TGF-1 activation and LM-332
expression as in subconﬂuent cultures, wounded monolay-
ers were treated with either LM609, IgG, RGD, or RGE. As
shown in Figure 8D, TGF-1 activation was signiﬁcantly
diminished by the treatment with LM609 or RGD (compared
with their respective controls, IgG and RGE). This reduction
in TGF-1 activation was accompanied with a reduction in
3 subunit mRNA expression (Figure 8D) and LM-332 ex-
pression shown by immunoﬂuorescence (Figure 8E).
In summary, these experiments clearly show that subcon-
ﬂuent cultures and wounded monolayers similarly activate
endogenous TGF-1, which signal via Smads and stimulate
LM-332 production in a mechanism dependent on LM609/
RGD.
DISCUSSION
Previous results from our laboratory demonstrated that
MDCK cells synthesize LM-332 only at subconﬂuent density
(Mak et al., 2006). In this study we have explored these
observations further to determine the mechanism responsi-
ble for regulated synthesis. We report that expression of the
3 and 2 chains is transcriptionally controlled as a function
of conﬂuence and that expression of at least the 3 subunit
is stimulated by TGF-1 acting through Smad2/Smad4
binding to an SBE found in the 3 promoter. Furthermore,
we ﬁnd that MDCK cells constitutively secrete inactive
TGF-1 independently of state of conﬂuence but only acti-
vate it when subconﬂuent through a mechanism involving
integrin V3.
Transcriptional regulation of LM-332 expression is known
to be complex. Early work showed that TGF- stimulated
LM-332 expression in keratinocytes (Korang et al., 1995), and
the laminin 3A promoter was found to have three AP-1
sites (linked to stimulation by TGF-), and an SRE (Virolle et
al., 1998). Later work also implicated other factors (Miller et
al., 2000, 2001; Virolle et al., 2002; Sathyanarayana et al.,
2003a,b; Fitsialos et al., 2008). More recently, Smad4 was
shown to regulate the synthesis of all three LM-332 chains
(Olsen et al., 2000; Zboralski et al., 2008).
Our results are consistent with a central role for TGF-1
and Smad signaling in the regulation of LM-332 expression.
In conﬂuent cultures of MDCK cells that do not express
LM-332, expression is stimulated by the addition of active
TGF-1. This artiﬁcially activated expression and normal
expression in subconﬂuent cells is blocked by an inhibitor of
the TR-I receptor that also blocks Smad2 phosphorylation,
formation of Smad2/Smad4 complexes, and translocation of
Smad4 to the nucleus. Transient expression of Smad2 and
Smad4 (but not Smad3) dominant-negative constructs sup-
presses laminin 3 transcription, and Smad4, presumably in
a complex with phospho-Smad2, binds to an SBE in the
laminin 3 promoter when LM-332 expression is activated.
We ﬁnd that conﬂuent MDCK cells secrete inactive
TGF-1 apically, in agreement with Murphy et al. (2004).
Our work extends these observations by describing an acti-
vation mechanism that is dependent on the integrin V3,
based on that the speciﬁcity of the function blocking anti-
body LM609 (Cheresh and Spiro, 1987; Cheresh et al., 1989;
Takagi et al., 1997). Under polarized conditions, inactive
TGF-1 presumably is unable to interact with either the
activation machinery dependent on V3 or with its recep-
tors, all of which are on the basolateral surface below the
tight junction. Our ﬁndings are also potentially consistent
with a recent study by Geng et al. (2009) who examined
TGF- signaling in the mouse proximal tubule cell line
BUMPT-306, and concluded that response to exogenous ac-
tivated TGF-1, as measured by Smad phosphorylation, de-
clined with conﬂuence (Geng et al., 2009). Given that the cells
in this study were grown on solid substrata instead of per-
meable supports, it is possible that the observed reduction in
signaling was due, in part, to the inability of TGF- in the
medium above the cells to access its receptors sequestered
below the tight junctions.
Several V-containing integrins have been implicated in
TGF- activation. Particularly, V3 has been shown to bind
through an RGD motif the LAP that sequesters TGF- (Lud-
brook et al., 2003; Dabovic and Rifkin, 2008; Goodwin and
Jenkins, 2009). Our results showing that soluble RGD pep-
tides can block TGF-1 activation (and thus LM-332 expres-
sion) support these ﬁndings. Other details about the mech-
anism of TGF-1 activation in MDCK cells are unknown at
this point. Some studies suggest that integrin-dependent
activation of TGF- also requires mechanical stretching of
the extracellular matrix-associated LAP, metalloendopro-
teases, or a combination to release the active TGF-1 (Hyy-
tiainen et al., 2004; Dabovic and Rifkin, 2008; Wells and
Discher, 2008). Indeed, some matrix metalloendoproteases
are only active in subconﬂuent MDCK cells (Moyano, Zuk,
and Matlin, unpublished), but it is not clear whether they
Figure 9. Proposed model for the regulation of LM-332 expression
by TGF-1 and the epithelial barrier. Conﬂuent (polarized) epithe-
lial cells form an intact epithelium with differentiated apical and
basolateral domains. Latent TGF-1 is secreted apically but is sep-
arated from the activation machinery (composed at least by integrin
V3) and the TGF- Receptor I (TR-I) by intact epithelial junc-
tional complexes. When the epithelium is wounded (cell–cell con-
tacts disrupted), latent TGF-1 is able to interact with integrin V3
which activates it by an unidentiﬁed mechanism dependent on RGD
[indicated by “? (RGD)”; see Discussion]. Activated TGF-1 then
binds to TR-I, initiating transcription and expression of LM-332
and facilitating the restoration of a continuous epithelium (reepi-
thelialization).
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MDCK cells, V3 is present on the free surface where it
could bind the inactive complex and relocate it to the sub-
stratum for activation via mechanical tension caused by cell
spreading. Further studies are necessary to discriminate be-
tween these possibilities.
Our results indicate that expression of LM-332 occurs
primarily through activation of Smad2 and not Smad3. Con-
sistent with this, transient expression of dominant-negative
Smad2 but not Smad3 constructs in subconﬂuent MDCK
cells suppresses expression of the laminin 3 mRNA. In
their study of TGF- and its receptors in MDCK cells, Mur-
phy et al. (2004) observed activation of both Smad2 and
Smad3 when active TGF-2 was added to the basolateral
side of polarized cells. The basis for the apparent discrep-
ancy between our results and those of Murphy et al. (2004) is
unclear.
It is well known that differential activation of Smad2 and
Smad3 can occur, but the exact molecular basis for this and
downstream consequences are not known (Brown et al.,
2007; Fu et al., 2009; Petersen et al., 2010). After binding of
TGF-1 to its receptors, phosphorylation of Smads by TR-I
is regulated by accessory proteins such as Smad anchor for
receptor activation (Wrana et al., 2008). In MDCK cells, it is
possible that such proteins are responsible for activation of
Smad2 over Smad3 under subconﬂuent conditions. In
MDCK and other renal cells, it is conceivable that activation
of Smad2 is more important in injury repair responses,
whereas Smad3 is involved in more dramatic alterations in
cells leading to epithelial–mesenchymal transformation and
ﬁbrosis. In support of this, Phanish et al., 2006 found that
Smad2 was responsible for increases in MMP-2 expression
in a transformed proximal tubule cell line, whereas changes
related to epithelial–mesenchymal transdifferentiation such
as loss of E-cadherin were Smad3 dependent.
Our laboratory reported previously that LM-332 expres-
sion in the rat kidney is signiﬁcantly up-regulated during
epithelial regeneration after ischemic injury (Zuk and Mat-
lin, 2002). If the in vitro results reported here are applied to
regenerative events in the rat kidney, then it would be
anticipated that TGF- is involved in the up-regulation of
LM-332. In fact, Basile et al. (1998) reported increased levels
of TGF-1 mRNA and its receptors in the rat kidney after
ischemic injury, and suggested that TGF-1 was responsible
for increased expression of a variety of extracellular matrix-
related genes. Expression of laminin isoforms was not ex-
amined. Basile’s group also injected neutralizing TGF-1
antibodies into the circulation of postischemic rats and ob-
served that the rates of renal tubular epithelial repair and
improvement in physiological measures of injury were not
impacted by the antibody (Spurgeon et al., 2005). Given our
ﬁndings and others (Murphy et al., 2004) demonstrating that
TGF-1 is secreted apically in MDCK cells, it is reasonable to
ask whether the circulating anti-TGF-1 antibodies in the
Basile experiments, which could only access the tubular
epithelium by passing through the interstitial space, were
effective in neutralizing TGF-1 at the level of the epithe-
lium. The well-recognized presence of TGF- in the urine of
normal individuals suggests that the polarity of the TGF-
response described here is not just an in vitro phenomenon
(Twardzik et al., 1982; Twardzik and Sherwin, 1985; Goum-
enos et al., 2002).
In summary, our results describe a novel mechanism for
regulation of LM-332 expression in epithelial cells (Figure 9).
In it, renal epithelial cells, and possibly other epithelial cells,
constitutively produce all of the components necessary to
initiate LM-332 expression, including latent TGF-, its re-
ceptors, and TGF- activation machinery. When the cells are
conﬂuent and polarized, TGF- can neither be activated nor
signal because it is separated from the activation machinery
and its receptors by the tight junctional barrier. When that
barrier is breached, then TGF- signaling ensues and LM-
332 expression commences without delay. To our knowl-
edge, this is only the second example of a signaling mecha-
nism whose regulation is dependent in part on the integrity
of an epithelial barrier (Vermeer et al., 2003), and the ﬁrst
such instance involving a component of the extracellular
matrix. An implication of this proposed mechanism is that
production of LM-332 is perhaps the most, proximal event
after breakdown of the epithelial barrier. As such, it is con-
ceivable that LM-332, acting through its receptors, helps to
reprogram injured epithelial cells for restoration of epithelial
continuity.
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